menu
    • menu

    Company profile for Ascendis Pharma

    NEW Drugs in Dev: 10
    Coral

    Virtual Booth

    Contact Supplier

    China’s top API & intermediate manufacturer, delivering advanced CMO/CDMO solutions to 60+ countries, empowering global health progress

    Virtual Booth

    Contact Supplier

    AMI Lifesciences is Driven by Chemistry. Powered by People.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    Alchem offers Botanical APIs for Pharmaceuticals, Cosmetics and Nutraceuticals// FDA-inspected and EU-GMP certified.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Ascendis Pharma is applying its innovative TransCon technology, which combines the benefits of prodrug and sustained-release technologies, to develop a pipeline of best‐in‐class therapeutics that address significant unmet medical needs. The TransCon technology can be applied to existing drug therapies, including proteins, peptides and small molecules, to create prodrugs that provide for the predictable and sustained releas...
    Ascendis Pharma is applying its innovative TransCon technology, which combines the benefits of prodrug and sustained-release technologies, to develop a pipeline of best‐in‐class therapeutics that address significant unmet medical needs. The TransCon technology can be applied to existing drug therapies, including proteins, peptides and small molecules, to create prodrugs that provide for the predictable and sustained release of an unmodified parent drug.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Ascendis PharmaDenmark Flag
    Country
    Country
    Denmark
    Address
    Address
    Tuborg Boulevard 12 2900 Hellerup Denmark
    Telephone
    Telephone
    +45 70 22 22 44
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://ascendispharma.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/ascendis-pharma-a-s/?originalSubdomain=in
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    PEGS Boston Summit

    PEGS Boston Summit

    Not Confirmed

    envelop Contact Supplier

    PEGS Boston Summit

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Ascendis Returns to Rare Endocrinology as Cancer Plans Falter
    Ascendis Returns to Rare Endocrinology as Cancer Plans Falter

    08 May 2026

    // BIOSPACE

    https://www.biospace.com/business/ascendis-retreats-to-rare-endocrinology-wheelhouse-as-cancer-plans-falter

    BIOSPACE
    08 May 2026
    Share Share
    2-Year ApproaCH Trial Data Show Growth Gains with TransCon CNP
    2-Year ApproaCH Trial Data Show Growth Gains with TransCon CNP

    06 May 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/05/06/3289301/0/en/new-2-year-data-from-pivotal-approach-trial-of-transcon-cnp-navepegritide-show-pronounced-gains-in-growth-outcomes-in-children-with-achondroplasia-aged-5-years.html

    GLOBENEWSWIRE
    06 May 2026
    Share Share
    Ascendis Reports Q1 2026 Results on May 7
    Ascendis Reports Q1 2026 Results on May 7

    30 Apr 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/04/30/3285424/0/en/ascendis-to-report-first-quarter-2026-financial-results-and-provide-business-update-on-may-7-2026.html

    GLOBENEWSWIRE
    30 Apr 2026
    Share Share
    Ascendis to Redeem $575M of 2.25% Convertible Notes
    Ascendis to Redeem $575M of 2.25% Convertible Notes

    21 Apr 2026

    // PRESS RELEASE

    https://investors.ascendispharma.com/news-releases/news-release-details/ascendis-announces-redemption-all-575-million-outstanding-225

    PRESS RELEASE
    21 Apr 2026
    Share Share
    Ascendis Pharma Shares Begin Trading on Nasdaq
    Ascendis Pharma Shares Begin Trading on Nasdaq

    20 Apr 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/04/20/3276963/0/en/ascendis-pharma-announces-commencement-of-trading-of-its-ordinary-shares-on-nasdaq.html

    GLOBENEWSWIRE
    20 Apr 2026
    Share Share
    Ascendis Pharma To List Ordinary Shares Directly On Nasdaq
    Ascendis Pharma To List Ordinary Shares Directly On Nasdaq

    08 Apr 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/04/08/3270368/0/en/Ascendis-Pharma-to-List-Ordinary-Shares-Directly-on-Nasdaq.html

    GLOBENEWSWIRE
    08 Apr 2026
    Share Share

    Inspections and registrations

    Upload your audits for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search